



# The aryl hydrocarbon receptor: dichotomously linking environmental signals to immune suppression and autoimmunity

Allison Ehrlich  
Assistant Professor  
Environmental Toxicology  
May 12, 2021




# Aryl hydrocarbon receptor (AhR): An environmental sensor

Environmental




Pharmacologic



Dietary





Bacterial Derived




# AhR is a ligand activated transcription factor

- A variety of immune cells, including **CD4<sup>+</sup> T cells**, express AhR.





# CD4<sup>+</sup> T cells orchestrate immune response outcomes








# AhR ligands can drive opposing T cell fates

- How do AhR impact CD4+ T cell responses during EAE (mouse model of MS)?
- TCDD has well established immunosuppressive activity
  - Long half life
- FICZ can be naturally found in cell culture culture media and skin (Trp + UVB)
  - Rapidly metabolized
- Both TCDD and FICZ are AhR agonists



# AhR ligands can drive opposing T cell fates



Quintana, F., Basso, A., Iglesias, A. et al. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. *Nature* 453, 65–71 (2008). <https://doi.org/10.1038/nature06880>




# How does activation of the same receptor lead to opposing outcomes?

**Story #1:** AhR-mediated modulation of CD4+ T cell differentiation is dependent on ligand dose, half-life, and receptor affinity (alloresponse model)

**Story #2:** AhR-mediated modulation of CD4+ T cell differentiation is dependent on tissue site (type 1 diabetes model)

# Parent-into-F1 alloresponse model






Donor T cells recognize Host antigen (presented by DCs) as foreign  
CD4<sup>+</sup> T cells prime CD8<sup>+</sup> cells to become cytotoxic (CTL)  
Donor CTLs destroy host cells (B cells as a readout)  
Host tissue destruction and weight loss




# Reported AhR ligand dosing regimens

## Treg Induction

Ligand	Dose	Regimen	Route	Selected References
	15µg/kg	1x	gavage	Funatake, J. Immunol., 2005; Kerkvliet, Immunotherapy, 2009; Schulz, Tox. Sci., 2012; Pauly, Toxicol. Environ. Chem., 2012; Quintana, Nature, 2008
	50µg/kg	Biweekly	gavage	
	15µg/kg	1x	gavage	
	50µg/kg	1x	i.p.	
	50µg/kg*	1x	i.p.	
	10mg/kg	1x/day	i.p.	Punj, PLoS One, 2014; Ehrlich, J. Immunol., 2016
	60mg/kg	3x/week	gavage	
	10mg/kg*	1x/day	i.p.	Quintana, PNAS, 2010; Nugen, IOVS, 2013
	10mg/kg*	1x/day	i.p.	

## Th17 Induction

Ligand	Dose	Regimen	Route	Selected References
	50µg/kg*	1x	i.p.	Quintana, Nature, 2008; Veldhoen, Nature, 2008; Schulz, Tox. Sci., 2012; Pauly, Toxicol. Environ. Chem., 2012; Singh, J. Immunol, 2016
	30µg/kg	1x	s.c.	
	50µg/kg	1x/3-4d	i.p.	
	100µg/kg	d-1 and 4	i.p.	
	50µg/kg	1x	gavage	

## DOCKING SCORE

	H AHR	M AHR
TCDD	-24.2	-22.15
ITE	-11.44	-13.43
<b>FICZ</b>	<b>-11.38</b>	<b>-11.24</b>
11BBQ	-10.98	-13.09


# Hypothesis

If administered at concentrations that equivalently induce and maintain AhR activation, different AhR ligands will induce similar effects on T cell activation/differentiation.


# Dose Determination

Doses were determined empirically, starting at 10mg/kg and adjusted based on *Cyp1a1* readout

**TCDD:** 15µg/kg 1x  
**11-Cl-BBQ:** 7.5mg/kg 1x/day  
**ITE:** 40mg/kg 4x/day  
**FICZ:** 10mg/kg 1x/day




# FICZ suppresses GVHD if administered at a dose that activates AhR equivalently to TCDD




# FICZ induces Tr1 cells when administered at doses that activate AhR equivalently to TCDD


Day 2




# Low dose FICZ administration induces IL-17



# CD4+ T cell fate is dependent on the extent of AhR activation



Ehrlich, A. and Kerkvliet, N. (2017) Current Opinion in Toxicology. 2:72-78.





Ehrlich A. et al. (2018) Toxicol Sci. 161(2):310-320.







# Hypothesis: Strong AhR activation will suppress the development of T1D


Diabetes incidence in NOD mice is dependent on housing environment




# Strong AhR activation suppresses insulinitis




12 weeks




20 weeks






12 weeks  
NOD.AHR<sup>KO</sup>




# Strong AhR activation increases the % of pancreatic Tregs



# Strong AhR activation suppresses Th17 cells




# Strong AhR activation “treats” T1D




# What about dietary AhR ligands?

Hypothesis: When given a **high dose** of the dietary AhR ligand precursor, indole-3-carbinol, NOD mice will have reduced insulinitis, mimicking studies with Cl-BBQ.


- In a GVH mouse model, different AhR ligands induce similar, dose-dependent, CD4<sup>+</sup> T cell differentiation outcomes if AhR activation is normalized
- NOD mice a lower sensitivity AhR allele (AhR<sup>d</sup>) (~10-fold, compared to C57BL/6 mice AhR<sup>b</sup>)
- In other C57BL/6 mouse models of inflammatory diseases, dietary I3C (100-2000ppm), promotes Tregs, decreases effector CD4 T cells, reduces immunopathology



I3C is broken down in the stomach into dimers, trimers and tetramers, some of which (e.g., ICZ) have high affinity for the AhR. (Linus Pauling Institute, Oregon State University)




# I3C strongly activates AhR in the intestine (not systemically)







# I3C promotes insulinitis






# I3C increases intestinal Th17 cells!



Analyzed Th17, Tr1, Foxp3+ Treg populations in the LP, IEL, Peyer's patch, spleen, pancreatic lymph node


Tissue	Significant host factors	Control (avg)	I3C (avg)	Ratio (I3C: Control)	p value
IEL	RORgt+Foxp3-	5.64	15.38	2.73	***
IEL	CD4+Lag3+Foxp3-	3.83	8.48	2.22	**
LPL	high scatter CD4-IL10R+	36.36	24.86	0.68	***
LPL	RORgt+Foxp3-	2.85	6.63	2.33	***
LPL	CD25+Foxp3-RORgt <sup>high</sup>	1.99	3.30	1.66	**
PP	Nrp1-Foxp3+	6.43	8.00	1.24	**
PP	RORgt+Foxp3-	2.48	4.22	1.71	**
PP	RORgt+Foxp3+	1.38	2.05	1.48	*
Spleen	CD4+IL-22+Foxp3-	0.64	0.87	1.37	**
Spleen	CD4+Nrp1 <sup>high</sup> Foxp3-	2.54	2.13	0.84	*
Spleen	CD4+CD25+Foxp3-	2.00	1.56	0.78	*
Pancreas	Insulitis (>50)	26.56	39.08	1.47	*
Ileum	Ileum Cyp1a1	1.88	439.77	233.92	***

# I3C alters gut microbial diversity




# Transkingdom network predicts microbe-Th17 interactions


**A**



**B**




**C**




\*Degree is the number of nodes each individual node interacts with, and measures the direct impact of one node has on other parameters in the system; bipartite betweenness centrality calculates the number of times the node lies in the shortest path connecting two groups of nodes, and more likely to be regulators of other nodes


**D**




**E**




**F**



**G**





**H**



# Speaking of AhR knockout mice...

- Strong systemic AhR activation (by TCDD and CI-BBQ) prevents T1D development.
- Intestinal AhR activation (by dietary I3C) exacerbates insulinitis.
- How does physiologic expression of AhR impact T1D development?**



# More questions than answers!

Why does I3C regulate immunopathology in C57BL/6 models, but not in NOD mice?

- opposite findings, disease exacerbation, no IL-22, decrease in butyrate-producing bacteria

- AhR allele sensitivity?

- background strain-specific differences?

- differences in IELs?

Why does systemic AhR activation and intestinal AhR activation lead to opposing Treg/Th17 ratios in NOD mice?

- differences in CD4+ T cell priming/microenvironment/role of microbiome?

Current studies using AhR knockout NOD mice (SPF and germ free) aim to answer the above questions!

# Some final thoughts on AhR immunotoxicology...

- Both immune activation and immune suppression can be problematic
  - desired vs undesired effects: toxicology vs pharmacology
- Low levels of exposure to AhR ligands can be problematic depending on the context!
- CD4+ T cell differentiation is just one arm of AhR-immune interactions
  - B cells
  - CD8 cells
  - Developmental immunotoxicology
  - Myeloid cell development/function
  - ILCs
  - Gut homeostasis (IELs, IECs)
  - Microbiome-AhR interactions




# Acknowledgements



Kristin Grimsrud  
Cassie Boers  
Taylor Hunsucker

Host Microbe Systems Biology Core  
Matt Rolston



Natalia Shulzhenko  
Andrey Morgun  
**Nolan Newman**

Nancy Kerkvliet  
Siva Kolluri  
**Jamie Pennington**

**Heather Kahalehili**  
**Keegan Malany**  
Kelsey Noliopovitch

Simone Sandoval  
Brendan McLaughlin  
Madison Carlin

Erin Winrow  
Jocelyn Molina



1K99DK117509-01  
4 R00 DK117509-03

UC Davis:  
Start up funding